Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women

• Status: Withdrawn
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

COVID-19 was declared a pandemic on March 11th. Efforts to save lives are essential as we will face increasing morbidity with rising demands on health care resources. Since pregnant women with COVID-19 have systematically been excluded from drug trials, potential treatment options for these high-risk individuals remain untested. The aim of our trial is to determine whether hydroxychloroquine given to COVID-19 positive pregnant women can reduce COVID-19-related hospital admissions, thereby allowing women to stay at home while limiting utilization of hospital resources and resulting exposure of health care providers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Women with a self-reported live pregnancy >14 weeks

• Presently in the outpatient setting (i.e. not admitted to the hospital)

• Tested positive for COVID-19 within last 7 days

• Must be living in Canada

Exclusion Criteria:

• Known glucose-6-phosphate dehydrogenase (G6PD) deficiency

• Known cardiac disease (or under investigation)

• Currently taking medication contraindicated as per Health Canada list for hydroxychloroquine

• Known retinopathy

• Known hypersensitivity to 4-aminoquinoline compounds

• Already taking hydroxychloroquine

• Unwilling to answer follow-up questionnaires

• Currently in labor

• Inpatient women at time of COVID-19 diagnosis.